Howard Cohen, RPh, MS, FASHP: Using Biosimilar Filgrastim

Video

Howard Cohen, RPh, MS, FASHP, director of oncology pharmacy services for Yale New Haven Hospital, discusses using biosimilar filgrastim.

Transcript:

Does your center use biosimilars?

We are currently using biosimilars. We’ve actually created an approval process that we accept biosimilars as an acceptable product. We have brought in the first biosimilar; we use the product Zarxio in place of Neupogen. We did a full review of the product—a clinical review, the manufacturing process of it—and made a decision based on efficacy, safety and of cost-savings.

Related Videos
Chelsee Jensen, PharmD, BCPS
GBW 2023 webinar
Ryan Haumschild, PharmD, MS, MBA
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD
Fran Gregory, PharmD, MBA
Julie Reed, MS
Julie Reed, executive director of the Biosimilars Forum
 Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health.
Related Content
© 2023 MJH Life Sciences

All rights reserved.